CardioVascular BioTherapeutics (fka CVBT)

[GoneforDays]

I asked my friend at VT about the valuation. He wouldn’t confirm nor deny the $21 share price. I did ask him if there we’re a valuation at this level would it surprise him. His answer:
“It wouldn’t surprise me that there could be a valuation over $7,000,000,000.
2 deals alone substantiate it. Avexys was bought by Novartis for $8.7 billion. They have 1 patent in what is now becoming a crowded market. Their treatment which has a total patient population of less than 10,000 people each year and has a $2m per patient price tag.
More recently The Medicine Co was also bought by Novartis. The price tag was $9.7 billion. They have 2 patents, 2 phase 1 trials and 2 phase 3 trials. They have no FDA approved products. Their drug is a better version of a statin – statins are now generic!”
So, $7 billion for VT seems reasonable. Apparently, the valuation doesn’t include the new VT303 molecule or recent IP.
BTW, I also received these emails from Gordon.
EMAIL 1
EMAIL 2